Natco Pharma Limited (NATCOPHARM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Natco Pharma Limited (NATCOPHARM) has a cash flow conversion efficiency ratio of 0.138x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs11.91 Billion ≈ $128.76 Million USD) by net assets (Rs86.54 Billion ≈ $935.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Natco Pharma Limited to measure how many days the company can operate on defensive assets alone.
Natco Pharma Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Natco Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Natco Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Natco Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Generate Biomedicines, Inc. Common Stock
NASDAQ:GENB
|
-0.156x |
|
Faraday Technology Corp
TW:3035
|
-0.038x |
|
Taiwan Secom Co Ltd
TW:9917
|
0.107x |
|
Sonida Senior Living Inc
NYSE:SNDA
|
-0.007x |
|
Petrovietnam Power Corp
VN:POW
|
-0.080x |
|
Sichuan Furong Technology Co Ltd
SHG:603327
|
-0.013x |
|
Guizhou Panjiang Refined Coal Co Ltd
SHG:600395
|
0.025x |
|
Kinpo Electronics Inc
TW:2312
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Natco Pharma Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Natco Pharma Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see NATCOPHARM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs76.12 Billion ≈ $823.24 Million |
Rs16.97 Billion ≈ $183.50 Million |
0.223x | +4.18% |
| 2024-03-31 | Rs58.53 Billion ≈ $632.99 Million |
Rs12.52 Billion ≈ $135.43 Million |
0.214x | +130.24% |
| 2023-03-31 | Rs91.37 Billion ≈ $988.18 Million |
Rs8.49 Billion ≈ $91.83 Million |
0.093x | +752.04% |
| 2022-03-31 | Rs42.64 Billion ≈ $461.09 Million |
Rs465.00 Million ≈ $5.03 Million |
0.011x | -84.95% |
| 2021-03-31 | Rs41.23 Billion ≈ $445.93 Million |
Rs2.99 Billion ≈ $32.31 Million |
0.072x | -34.28% |
| 2020-03-31 | Rs37.85 Billion ≈ $409.30 Million |
Rs4.17 Billion ≈ $45.13 Million |
0.110x | -42.45% |
| 2019-03-31 | Rs34.91 Billion ≈ $377.54 Million |
Rs6.69 Billion ≈ $72.33 Million |
0.192x | +27.11% |
| 2018-03-31 | Rs30.76 Billion ≈ $332.66 Million |
Rs4.64 Billion ≈ $50.14 Million |
0.151x | -27.94% |
| 2017-03-31 | Rs16.53 Billion ≈ $178.81 Million |
Rs3.46 Billion ≈ $37.40 Million |
0.209x | +166.23% |
| 2016-03-31 | Rs13.03 Billion ≈ $140.94 Million |
Rs1.02 Billion ≈ $11.07 Million |
0.079x | -27.85% |
| 2015-03-31 | Rs8.51 Billion ≈ $92.04 Million |
Rs926.66 Million ≈ $10.02 Million |
0.109x | -44.61% |
| 2014-03-31 | Rs7.33 Billion ≈ $79.24 Million |
Rs1.44 Billion ≈ $15.58 Million |
0.197x | +74.77% |
| 2013-03-31 | Rs5.44 Billion ≈ $58.84 Million |
Rs611.95 Million ≈ $6.62 Million |
0.112x | -18.24% |
| 2012-03-31 | Rs4.72 Billion ≈ $51.05 Million |
Rs649.41 Million ≈ $7.02 Million |
0.138x | -28.06% |
| 2011-03-31 | Rs3.53 Billion ≈ $38.23 Million |
Rs675.97 Million ≈ $7.31 Million |
0.191x | -23.21% |
| 2010-03-31 | Rs3.11 Billion ≈ $33.60 Million |
Rs773.69 Million ≈ $8.37 Million |
0.249x | +77.24% |
| 2009-03-31 | Rs2.66 Billion ≈ $28.77 Million |
Rs373.85 Million ≈ $4.04 Million |
0.141x | -34.64% |
| 2008-03-31 | Rs2.25 Billion ≈ $24.34 Million |
Rs483.90 Million ≈ $5.23 Million |
0.215x | -11.13% |
| 2007-03-31 | Rs1.86 Billion ≈ $20.12 Million |
Rs450.03 Million ≈ $4.87 Million |
0.242x | +19.35% |
| 2006-03-31 | Rs1.54 Billion ≈ $16.64 Million |
Rs311.81 Million ≈ $3.37 Million |
0.203x | -52.96% |
| 2005-03-31 | Rs1.14 Billion ≈ $12.29 Million |
Rs489.69 Million ≈ $5.30 Million |
0.431x | -- |
About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; a… Read more